Enhanced Anti-Lung Cancer Efficacy of Neo-BCV Combined with Cisplatin: Immune Activation and Tumor Microenvironment Remodeling
Open Access
Abstract
Background: Lung cancer is the top cause of cancer-related mortality globally, and chemo-immunotherapy is a core therapeutic strategy for it. The novel bacterial composite vaccine (Neo-BCV) we developed previously can activate anti-tumor immunity. This study explored its synergistic anti-tumor effect with cisplatin (CDDP), along with the underlying immunomodulatory mechanisms and molecular regulatory networks. Methods: A murine Lewis lung cancer (LLC) model was established to evaluate the efficacy of the combination therapy. Flow cytometry and multiplex cytokine assay were used to detect immune cell subsets and functional molecules in the spleen, serum and tumor tissues. RNA-sequencing (RNA-seq) was used to elucidate the molecular regulatory networks following the combination therapy in the tumor tissues. Body weight, blood indexes, serum biochemistry and H&E staining were monitored to verify biosafety. Results: Neo-BCV combined with CDDP achieved an 87.77% tumor growth inhibition rate, showing the most significant anti-tumor effect. The combination promoted DC maturation, enhanced effector immune cell infiltration, reduced immunosuppressive cells, upregulated Th1-type cytokines and downregulated CD8+ T cell surface PD-1. RNA-seq confirmed enrichment of multiple immune effector pathways, supporting tumor immune microenvironment remodeling. The combination alleviated CDDP-induced weight loss, had no obvious adverse effects on physiological indicators, and exhibited good biosafety. Conclusions: Neo-BCV combined with CDDP achieves enhanced anti-tumor efficacy and favorable biosafety in murine lung cancer models by regulating immune cell subsets and activating immune-related molecular pathways, providing a solid preclinical basis for its clinical translation in lung cancer treatment.Keywords
Funding Information
- Jiangsu Provincial Department of Finance (BK20241761)
- Third Level Talents of the “333 High Level Talents Training Project”
This publication has 56 references indexed in Scilit:
- Tumor-infiltrating B cells: Their dual mechanistic roles in the tumor microenvironmentBiomedicine & Pharmacotherapy, 2024
- Drug‐Loaded Bacillus Calmette–Guérin Bacteria for Immuno‐Chemo Combo Therapy in Bladder CancerAdvanced Materials, 2024
- Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockadeClinical & Experimental Metastasis, 2024
- Bacterial‐Mediated Tumor Therapy: Old Treatment in a New ContextAdvanced Science, 2023
- Cisplatin in cancer treatmentBiochemical Pharmacology, 2022
- NK Cells in the Tumor Microenvironment2020
- B Cell Development and Maturation2020
- IL-17A and IL-17F orchestrate macrophages to promote lung cancerCellular Oncology, 2020
- Magnetic fields enhance the anti-tumor efficacy of low dose cisplatin and reduce the nephrotoxicityNaunyn-Schmiedeberg's Archives of Pharmacology, 2020
- Links between cancer metabolism and cisplatin resistance2020